Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Genome-wide maps of chromatin state in MDA-MB-231 cells [ChIP-seq]

ABSTRACT: We report a series of ChIP-Seq results in MDA-MB-231 cells. Briefly, we performed ChIP-Seq experiments with antibodies specific for PHF20L1, MTA1, EZH2, H3K27me2, H3K27me3 and H3K27ac in normal or knockdown of PHF20L1 MDA-MB-231 cells . We found that knockdown of PHF20L1 reduced the enrichment of MTA1, EZH2, H3K27me2, and H3K27me3 on the PHF20L1 target gene, and the enrichment of H3K27ac increased. This study gave us a new understanding of the role of PHF20L1 in chromatin status and gene transcription.

ORGANISM(S): Homo sapiens

PROVIDER: GSE128231 | GEO | 2020/03/12

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Similar Datasets

Regulatin of KDM5C stability and enhancer reprogramming in breast cancer [ChIP-Seq]

Project description:We report the high-throughput profiling of histone modifications( H3K4me3 and H3K27ac) inTRIM11 knockdown and KDM5C knockdown MDA-MB-231 cells. we generated genome-wide chromatin-state maps of MDA-MB-231 cells.This study provides the localization of H3K4me3 and H3K27ac on chromatin in TRIM11 knockdown and KDM5C knockdown MDA-MB-231 cells.

2022-10-27 | GSE185832 | GEO

Breast cancer cell lines treated with EZH2 inhibitor compounds

Project description:Loss of H3K27me3 repressive chromatin histone marks, maintained by the histone methyltransferase (HKMT) EZH2, may lead to reversal of epigenetic silencing in tumor cells and have therapeutic potential. Using a cell-based assay, we have identified three compounds from a HKMT inhibitor chemical library which re-express H3K27me3 mediated, silenced genes. Chromatin immunoprecipitation verified a decrease in silencing marks (H3K27me3, H3K9me3) and importantly an increase in active marks (H3K4me2/3, H3K27ac) at the promoter of re-expressed genes. Compound treated breast tumor cells induced enrichment for genome-wide changes in expression of known target genes for EZH2 and induced cell growth inhibition: with most sensitive breast tumor cell lines having low EZH2 protein expression, while a normal epithelial breast line was least sensitive. Agilent SurePrint G3 Human 8x60k two-colour microarrays were used to profile gene expression changes induced by treatment with drug compounds in MDA MB-231 cells, both at 24h and 48h. 4 replicates were used for each drug, time combination. A separate untreated control sample was used for comparison with each replicate.

2013-08-27 | E-GEOD-36131 | biostudies-arrayexpress

Genome wide map of EZH2 and SOX2 binding in mammospheres reveals common set of bound regions.

Project description:We generated genome wide map of EZH2 and SOX2 protein binding in MDA-MB-231 mammospheres and we discovered enrichment of both protein on the genes regulated by SCIRT

2021-02-23 | GSE136187 | GEO

Gene expression profile in breast cancer cells

Project description:We report the gene expression patterns in MDA-MB-231 (a line selected for low metastatic ability), MDA-MB-231-1833 (its bone-tropic metastatic derivative line), MDA-MB-231p27CK-DD (a phosphomimetic cell line), MDA-MB-231-1833shp27 (p27 knockdown cell line), MDA-MB-231-1833PF1502 (PI3K inhibitor treatment). It shows that the gene expression pattern are regulated in a p27 phosphorylation-dependent manner.

2019-03-19 | GSE112445 | GEO

MDA-MB-231 cells: shMUC4 transfected vs. Control SCR

Project description:Identification of MUC4-associated expression of genes by comparing MUC4 knockdown (MDA-MB-231-shMUC4) and control (MDA-MB-231-SCR).

2012-12-31 | GSE40157 | GEO

Estrogen receptor beta repurposes EZH2 to suppress oncogenic NFκB signaling in triple negative breast cancer [ChIP-Seq]

Project description:The purpose of this study was to elucidate the effects of ERβ on the genomic distribution of NFκB and RNA Polymerase II phospho-Ser2, as well as changes in H3K27me3, H3K27ac, in MDA-MB-231 triple negative breast cancer cells.

2020-09-30 | GSE155684 | GEO

LC-MSMS MDA-MB-231 with knockdown of ELOVL5 and IGFBP6 genes

Project description:Identification of changes in protein expression by label-free shotgun proteomics in breast cancer MDA-MB-231 cells with knockdown of ELOVL5 and IGFBP6 genes in comparison with control MDA-MB-231 cells.

2021-05-20 | PXD023892 | Pride

Identification of enhancer landscape in MDA-MB-231 cells

Project description:To identify typical enhancers and super-enhancers in the MDA-MB-231 triple-negative breast cancer cell line, we performed ChIP-seq using DNA isolated from untreated MDA-MB-231 cells using an H3K27ac antibody.

2020-02-21 | GSE95222 | GEO

EZH2 Overexpression in Breast Cancer is due to MicroRNA-Dependent Suppression of ZBTB4

Project description:In order to Sp1 and EZH2-specific gene expression pattern in breast cancer, small interfering RNA for Sp1 and EZH2 was transfected in MDA-MB-231 cells. Four groups of samples are included: 1. si control (siCT_1, siCT_2, siCT_3). 2. siSp1 (siSp1_1, sisSp1_2, siSp1_3). 3. si control (siCT_A, siCT_B, siCT_C). 4. siEZH2 (siZEH2_1, siZEH2_2,siEZJ2_3). Gene expression profiles of Sp1 and EZH2 depleted cells were compared to that of siRNA controls. Experiments were performed in MDA-MB-231 cells.

2015-03-02 | E-GEOD-48979 | biostudies-arrayexpress

Differential gene expression analysis of RNAseq data comparing control and srGAP1 knockdown MDA-MB-231 primary tumors.

Project description:To investigate the differential expression of genes in human tumor xenografts of control MDA-MB-231 primary tumors (Ctrl) and srGAP1 knockdown MDA-MB-231 primary tumors.

2022-08-10 | GSE210488 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data